Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma

Cancer Science

Volumn 98, Issue 1, 2007, Pages 109-112

  Niitsu, Nozomi ^a   Kohori, Mika ^a   Higashihara, Masaaki ^b   Bessho, Masami ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATININE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MITOXANTRONE; TROPONIN T;

AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ECG ABNORMALITY; ECHOCARDIOGRAPHY; ELDERLY CARE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, T-CELL; MALE; MITOXANTRONE; NATRIURETIC PEPTIDES; NEOPLASM RECURRENCE, LOCAL; STROKE VOLUME; TROPONIN T; VENTRICULAR FUNCTION, LEFT;

EID: 33751310375     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00349.x     Document Type: Article

References (24)

1. The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 2000; 50: 696-702.
2. Pinkus GS, Said JW. Periperal T-cell lymphoma. In: Daniel MK, ed. Neoplastic Hematopathology. Baltimore: Williams & Wilkins, 2001: 1091-164.
3. Vose JM. The International PTCL Project International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: Poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood 2005; 106: 811.
4. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-95.
5. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76-82.
6. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: Update and perspectives. Cancer Chemother Pharmacol 1993; 32: 103-8.
7. Ohno R, Yoshida Y, Oguro M et al. An early phase II study of CPT-11 (Irinotecan hydrochloride) in patients with hematological malignancies. Jpn J Cancer Chemother 1994; 21: 75-82.
8. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992; 50: 604-10.
9. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 1992; 50: 760-6.
10. Coltman CA Jr, Coltman TM, Balcerzak SP, Morrison FS, Von Hoff DD. Mitoxantrone in refractory non-Hodgkin's lymphoma: A Southwest Oncology Group study. Semin Oncol 1984; 11: 50-3.
11. Niitsu N, Iijima K, Chizuka A. Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: A pilot study. Ann Hematol 2001; 7: 411-16.
12. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
13. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1.
14. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI-Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-53.
15. Ishii J, Cui W, Kitagawa F et al. Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 2003; 49: 2020-6.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
17. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-26.
18. Haller DG. An overview of adjuvant therapy for colorectal cancer. Eur J Cancer 1995; 31A: 1255-63.
19. Sarris AH, Phan A, Goy A et al. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas: Indications of activity in a phase II trial. Oncology 2002; 16: 27-31.
20. Ribrag V, Koscielny S, Vantelon JM et al. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas. Leuk Lymphoma 2003; 44: 1529-33.
21. Nousiainen T, Vanninen E, Jantunen E et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002; 251: 228-34.
22. Auner HW, Tinchon C, Linkesch W et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82: 218-22.
23. Koh E, Nakamura T, Takahashi H. Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 2004; 68: 163-7.
24. Niitsu N, Kohuri M, Higashihara M, Bessho M. Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma. Cancer Sci 2006; 97: 933-7.